If you had any doubt why Pfizer, GlaxoSmithKline, and other Big Pharma companies are drooling over business in the developing world, take a look at a new Deutsche Bank report on the Indian drug market. Rising population and a growing middle class are expected to push drug sales up by 8 percent annually--much higher than the growth rate predicted for elsewhere in the world. By 2015, sales in the subcontinent are expected to surpass $31 billion.
- see the coverage in the Economic Times